Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill
tumor cells. Combining bryostatin 1 with interleukin-2 may kill more tumor cells.
PURPOSE: Randomized phase I trial to study the effectiveness of interleukin-2 plus bryostatin
1 in treating patients who have melanoma or kidney cancer that cannot be removed during
surgery.